Background
==========

Primary angiosarcoma of the spleen is an extremely rare malignancy, the pathogenesis of which is unknown, with high metastatic potential and a very poor prognosis. This aggressive disease usually presents in adults in their sixth to seventh decade. The reported median survival rates range from 4.4 to 14 months \[[@B1],[@B2]\]. These mesenchymal tumors can easily be neglected and splenic rupture is the most frequently manifestation at the time of diagnosis. We report a case of spontaneous splenic rupture due to angiosarcoma in a 65-year-old man.

Case presentation
=================

A 65-year-old man was admitted with diffuse abdominal pain and distention. The pain was constant and dull, and started 2 hours prior to admission with no obvious inducible factor. The patient's past medical history was unremarkable except mild weight loss during the recent 5 months. Physical examination revealed a palpable abdominal mass in the left upper abdominal quadrant with tenderness, and the patient's hemodynamic condition was unstable with systolic arterial blood pressure only 85 mmHg and heart rate 110 beats/minute. After initial fast fluid resuscitation (1,000 ml hetastarch 130/0.4 NaCl), the hemodynamic status of the patient became stable. Peripheral blood count revealed anemia (hemoglobin 10.0 g/dl) and thrombocytopenia (platelets 90 × 10^9^/l), but it did not reach disseminated intravascular coagulopathy. Results of other laboratory examinations had not been reported to us before the operation due to the emergency. Abdominal ultrasonography showed an enlarged spleen filled with irregular nodules, multiple hepatic solid lesions and moderate accumulation of peritoneal fluid. Abdominal paracentesis was performed with blood fluid aspirated from the peritoneal cavity. These findings were further confirmed by an abdominal computed tomography scan (Figure [1](#F1){ref-type="fig"}), demonstrating a heterogeneous, low-density signal within the splenic parenchyma, with variable degrees of contrast enhancement as well as intra-abdominal hemorrhage originating most possibly from the spleen. Meanwhile, there were multiple low-density lesions with enhanced rim in the liver.

![**Enlarged spleen completely replaced by low-density tumor tissue and multiple hypervascular metastases in liver.** Contrast-enhanced image in the portal venous phase computed tomography scan showing the enlarged spleen completely replaced by tumor tissue with low density and multiple hypervascular metastases in the liver with sizes varying from 5 mm to 2 cm. Some free fluid around the liver and spleen was also found, indicating intraperitoneal hemorrhage.](1477-7819-11-53-1){#F1}

Laparotomy revealed a huge spleen actively bleeding and an abnormal liver with several metastatic foci. We did observe a fissure of the capsule of the spleen with a size of 6 cm (length) × 2.5 cm (depth) in the lower pole of spleen. Two liters of blood had been collected from the peritoneal cavity. Splenectomy was performed. During the procedure, the patient received 4 units of concentrated red blood cells and 2 units of fresh frozen plasma.

The spleen was 1,650 g in weight, 19 cm × 16 cm × 11 cm in size, with nodular appearance and bleeding. The pathology diagnosis of the excised spleen was angiosarcoma originating from the spleen (Figure [2](#F2){ref-type="fig"}). Immunohistochemical staining was positive for vimentin (Figure [3](#F3){ref-type="fig"}), CD31 (Figure [4](#F4){ref-type="fig"}), CD34 (Figure [5](#F5){ref-type="fig"}), factor VIII (Figure [6](#F6){ref-type="fig"}), a1ACT (Figure [7](#F7){ref-type="fig"}) and SMA (Figure [8](#F8){ref-type="fig"}), and was negative for lysozyme (Figure [9](#F9){ref-type="fig"}). The Ki-67 proliferation index was less than 10% (Figure [10](#F10){ref-type="fig"}).

![**Histopathologic findings of the spleen angiosarcoma.** Spindle tumor cells have replaced the normal red and white pulp in the spleen, whereas ecstatic vascular spaces lined with hypertrophied endothelial cells are apparent.](1477-7819-11-53-2){#F2}

![Specimen stained positive for vimentin.](1477-7819-11-53-3){#F3}

![Specimen stained positive for CD31.](1477-7819-11-53-4){#F4}

![Specimen stained positive for CD34.](1477-7819-11-53-5){#F5}

![**Specimen stained positive for factorVIII.**](1477-7819-11-53-6){#F6}

![Specimen stained positive for a1ACT.](1477-7819-11-53-7){#F7}

![Specimen stained positive for SMA.](1477-7819-11-53-8){#F8}

![Specimen stained negative for lysozyme.](1477-7819-11-53-9){#F9}

![Ki-67 proliferation index less than 10%.](1477-7819-11-53-10){#F10}

Discussion
==========

Angiosarcoma originated from the spleen is an extremely rare malignant tumor, which affects 0.14 to 0.25 per million people \[[@B3]\]. People at any age may develop this disease. The presentation age is between 14 months and 89 years. This neoplasm shows a slight male predominance \[[@B3]-[@B5]\]. We reviewed related literatures and summarized the data (Table  [1](#T1){ref-type="table"}).

###### 

Data of the published literatures regarding splenic rupture secondary to splenic angiosarcoma

  **Gender**   **Age**       **Clinical manifestations**                 **Laboratory result**      **Early metastasis**                            **Treatment**                  **Prognosis**                              **Reference**
  ------------ ------------- ------------------------------------------- -------------------------- ----------------------------------------------- ------------------------------ ------------------------------------------ ---------------
  Female       45            Left upper abdominal pain and mass, shock   Anemia, thrombocytopenia   Early multiple metastases                       Splenectomy and chemotherapy   Died 4 months after surgery                \[[@B6]\]
  Female       79            None                                        Anemia                     No                                              Splenectomy                    Discharged on the 10th postoperative day   \[[@B7]\]
  Female       17            Shock, left upper abdominal pain and mass   Anemia, thrombocytopenia   No                                              Splenectomy                    Disease-free of 16 months                  \[[@B8]\]
  Female       45            Left upper abdominal pain                   Thrombocytopenia           Liver metastases after 3 months                 Splenectomy and chemotherapy   Died 7 months after surgery                \[[@B9]\]
  Male         57            Upper abdominal pain, shock                 Anemia, thrombocytopenia   Early liver metastases                          Splenectomy                    Died 1 day after surgery                   \[[@B10]\]
  Female       64            Fatigue, upper abdominal pain               Thrombocytopenia           Early bone metastases                           Splenectomy and chemotherapy   Died 4 months after surgery                \[[@B11]\]
  Male         76            Upper abdominal pain, shock                 Anemia, thrombocytopenia   Peritoneal and liver metastases after 4 weeks   Splenectomy                    Died 6 weeks after splenectomy             \[[@B12]\]
  Female       37            Left upper abdominal pain                   Anemia                     Liver metastases                                Splenectomy and chemotherapy   Died 6 months after surgery                \[[@B13]\]
  Male         53            Upper abdominal pain, shock                 Anemia, thrombocytopenia   Early liver metastases                          Splenectomy                    Died 7 months after surgery                \[[@B14]\]
  Female       35            Upper abdominal pain, shock                 None                       Early liver metastases                          Splenectomy                    Died 4 day after surgery                   \[[@B15]\]
  Female       80 and over   Shock                                       Anemia                                                                     Splenectomy                                                               \[[@B16]\]
  Female       Middle age                                                                           Early liver metastases                          Splenectomy                                                               \[[@B17]\]

Although the pathogenesis of this tumor is not clear, ionizing radiation, arsenic, vinyl chloride and chemotherapy for lymphoma have been implicated as causative factors \[[@B18],[@B19]\], and it has been reported that the angiosarcoma requires the existence of a benign pathology such as hemangioma or hemangioendothelioma \[[@B18],[@B20]\]. However, there was no evidence of any of these factors involved in our case.

Clinical presentation of splenic angiosarcoma is variable. Left upper abdominal pain is the most common symptom \[[@B5]\]. Other complaints include fatigue, weight loss, and anorexia. Splenomegaly is the most common physical examination finding \[[@B5]\]. Hepatomegaly and left upper quadrant mass are other two common findings. The most serious manifestation is splenic rupture, which often leads to fatal hemorrhage \[[@B21]\].

Laboratory examination can find cytopenia, leukocytosis, thrombocytosis and elevated erythrocyte sedimentation rate. Anemia and thrombocytopenia are presented in more than 50% cases \[[@B3],[@B11]\].

Imaging examinations are helpful for the differential diagnosis, although lacking accuracy. The most common ultrasonography findings are splenomegaly and ill-defined solid and cystic masses in the spleen with heterogeneous echotexture \[[@B22],[@B23]\]. The areas of hemorrhage and necrosis within the tumors are frequently shown as cystic areas. Increased blood flow may be detected in the solid part of the masses on color Doppler images. Computed tomography may reveal an enlarged spleen with hypo-attenuating or hyper-attenuating areas with punctate or massive calcification on plain computed tomography scan (without contrast agent infused) \[[@B24],[@B25]\]. Areas with hyper-attenuation are likely to reflect acute hemorrhage. On contrast-enhanced computed tomography scans, the tumors may exhibit peripheral or heterogeneous enhancement similar to that of hepatic cavernous hemangiomas \[[@B26],[@B27]\]. On magnetic resonance imaging, ill-defined nodular lesions with low or high signal intensity may be seen on both T1-weighted and T2-weighted images. High signal intensity on both T1-weighted and T2-weighted images is related to subacute hemorrhage or tumor necrosis, and low signal intensity is related to chronic hemorrhage or fibrosis within the tumor \[[@B28]\].

Biopsy is contraindicated in splenic angiosarcoma because of high risk of rupture. Histologic studies can therefore only be made after splenectomy. Microscopic examinations reveal freely anastomosing papillary and classical characteristic vascular channels lined by masses of endothelial cells \[[@B4]\]. Immunohistochemically, at least two vascular proliferation markers (CD31, CD34, and factor VII) plus at least one histiocytic differentiation marker (lysozyme and/or CD68) are required to makes the diagnosis \[[@B5]\].

This tumor has a high incidence of early metastasis, as reflected in the reported rates of between 69% and 100%, with the most common sites being in the liver, lungs, bones or bone marrow, lymph nodes, gastrointestinal tract, brain and adrenal glands \[[@B3],[@B5],[@B29]\]. Our patient, however, had metastases in the liver.

Our case died 6 months after the surgery. Primary splenic angiosarcomas are very aggressive neoplasms, with a median survival of 5 months irrespective of treatment. Neuhauser and colleagues reported that 93% of patients died with disseminated tumor within 29 months \[[@B5]\]. Early diagnosis with splenectomy can result in a much more favorable survival rate \[[@B3],[@B21]\], but it is very difficult.

Conclusions
===========

Splenic angiosarcoma is very rare but has a poor prognosis. It may cause secondary spontaneous rupture, resulting in fatal hemorrhage, which should be paid sufficient attention. Immediate surgery is necessary but the outcome is still unsatisfactory. Attempts should be made to improve the outcome by developing new techniques.
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